Evidence map›Paper›PMID 27936416›Full record

ArticleBiomaterials2017

Antigen recognition-triggered drug delivery mediated by nanocapsule-functionalized cytotoxic T-cells.

R Brad Jones, Stephanie Mueller, Sudha Kumari, Vlad Vrbanac, Shy Genel, Andrew M Tager, Todd M Allen, Bruce D Walker, Darrell J Irvine

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 79 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Tailoring biomaterials for vaccine delivery.Journal of nanobiotechnology · 2024
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Synthetic cells in biomedical applications.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022
    Review
  10. Article
  11. Review
  12. Article
  13. Cell-Based Tracers as Trojan Horses for Image-Guided Surgery.International journal of molecular sciences · 2021
    Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Immunomodulatory Nanosystems.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

R Brad JonesRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA; Dept of Microbiology, Immunology, and Tropical Medicine, The George Washington University, Washington DC, USA; Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.
Stephanie MuellerRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA; Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.
Sudha KumariRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA; Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.
Vlad VrbanacRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA; Center for Immunology and Inflammatory Diseases, MGH, Boston, MA, USA.
Shy GenelAstronomy Dept., Columbia University, New York, NY, USA.
Andrew M TagerRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Todd M AllenRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Bruce D WalkerRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA; Dept. of Microbiology and Immunology, Harvard Medical School, Boston, MA, USA; Dept. of Biological Engineering, MIT, Cambridge, MA, USA; Dept. of Materials Science & Engineering, MIT, Cambridge, MA, USA.
Darrell J IrvineRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA; Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA; Dept. of Biological Engineering, MIT, Cambridge, MA, USA; Dept. of Materials Science & Engineering, MIT, Cambridge, MA, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA. Electronic address: djirvine@mit.edu.
Ragon Institute of MGH, MIT and Harvard · USAllen Institute · USColumbia University · US

Funding

BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral EradicationUM1AI126617 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI JONES, R. BRAD, NIXON, DOUGLAS F · 2016 to 2020
$28.1M
P3: Chemokine-Mediated T Cell Trafficking in HIV Transmission and Immune ResponseP01AI112521 · NIAID · HARVARD MEDICAL SCHOOL · PI VON ANDRIAN, ULRICH H · 2014 to 2018
$9.8M
The District of Columbia Developmental Center for AIDS Research (DC D-CFAR)P30AI087714 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI GREENBERG, ALAN EDWARD · 2010 to 2014
$8.4M
T-cell-mediated targeting of therapeutics to HIV reservoirsR01AI111860 · NIAID · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI IRVINE, DARRELL J, JONES, R. BRAD · 2014 to 2018
$2.1M
Howard Hughes Medical InstituteNIAID NIH HHS P01 AI112521NIAID NIH HHS P30 AI087714NIAID NIH HHS R01 AI111860NIAID NIH HHS UM1 AI126617
6 · The paper itself

Abstract

Cytotoxic T-Lymphocytes (CTLs) kill pathogen-infected or transformed cells following interaction of their T-cell receptors (TCRs) with foreign (e.g. virus-derived) peptides bound to MHC-I molecules on the target cell. TCR binding triggers CTLs to secrete perforin, which forms pores in the target cell membrane, promoting target death. Here, we show that by conjugating drug-loaded lipid nanoparticles to the surface of CTLs, their lytic machinery can be co-opted to lyse the cell-bound drug carrier, providing triggered release of drug cargo upon target cell recognition. Protein encapsulated in T-cell-bound nanoparticles was released following culture of CTLs with target cells in an antigen dose- and perforin-dependent manner and coincided with target cell lysis. Using this approach, we demonstrate the capacity of HIV-specific CTLs to deliver an immunotherapeutic agent to an anatomical site of viral replication. This strategy provides a novel means to couple drug delivery to the action of therapeutic cells in vivo.

Indexed as

AnimalsAnti-HIV AgentsAutoantigensDelayed-Action PreparationsHIV InfectionsMiceNanocapsulesT-Lymphocytes, CytotoxicAnti-HIV AgentsAutoantigensDelayed-Action PreparationsNanocapsulesCytotoxic T lymphocytesDrug deliveryImmunotherapyLipid nanocapsulesT-pharmacyte

Identifiers

PMID27936416
PMCPMC5204257
OpenAlexW2557000257

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.